NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAFCIT (caffeine citrate) is an intravenous solution containing caffeine citrate approved in 1999 for neonatal apnea of prematurity. It is a central nervous system stimulant that increases respiratory drive and reduces periodic breathing episodes in preterm infants. The drug works by blocking adenosine receptors and enhancing neuronal excitability.
LOE Approaching
Niche neonatal ICU product with stable but limited market, indicating small specialized teams and transition-focused strategy planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CAFCIT offers exposure to niche neonatal therapeutics with deep hospital relationships and specialized clinical knowledge, but limited career growth due to LOE and zero linked job openings. Career value lies in understanding product lifecycle management, patent defense, and transition strategy in a consolidating neonatal market.
Product ManagerMedical Science Liaison
Worked on CAFCIT at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.